These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 32132028

  • 1. Human Glioma Cells Acquire Temozolomide Resistance After Repeated Drug Exposure Via DNA Mismatch Repair Dysfunction.
    Yamashiro K, Nakao K, Ohba S, Hirose Y.
    Anticancer Res; 2020 Mar; 40(3):1315-1323. PubMed ID: 32132028
    [Abstract] [Full Text] [Related]

  • 2. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP.
    Clin Cancer Res; 2020 Apr 01; 26(7):1690-1699. PubMed ID: 31900275
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
    Hayashi T, Adachi K, Ohba S, Hirose Y.
    J Neurooncol; 2013 Nov 01; 115(2):169-78. PubMed ID: 23943501
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH, Chang TY, Lin WC, Wei KC, Shin JW.
    Sci Rep; 2017 Aug 18; 7(1):8814. PubMed ID: 28821714
    [Abstract] [Full Text] [Related]

  • 10. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M.
    J Neurochem; 2012 Jul 18; 122(2):444-55. PubMed ID: 22564186
    [Abstract] [Full Text] [Related]

  • 11. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
    Yuan AL, Meode M, Tan M, Maxwell L, Bering EA, Pedersen H, Willms J, Liao J, Black S, Cairncross JG, Blough MD.
    J Neurooncol; 2020 Jul 18; 148(3):463-472. PubMed ID: 32562246
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.
    Lang F, Cornwell JA, Kaur K, Elmogazy O, Zhang W, Zhang M, Song H, Sun Z, Wu X, Aladjem MI, Aregger M, Cappell SD, Yang C.
    Neuro Oncol; 2024 Jun 03; 26(6):1083-1096. PubMed ID: 38134889
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
    Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper RO.
    J Neurosurg; 2003 Mar 03; 98(3):591-8. PubMed ID: 12650433
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
    Liang H, Chen Z, Sun L.
    Mol Carcinog; 2019 Aug 03; 58(8):1502-1511. PubMed ID: 31045274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.